ReviewOncoTargets and therapy2020
Cervical Cancer: Emerging Immune Landscape and Treatment.
Review in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Interaction of circular RNAs with splicing factors in cervical cancer: Modulation, interplay and theranostics (Review).Molecular medicine reports · 2026Review
- Cell-Mediated Immunity Against Human Papillomavirus Infection: From Viral Clearance to Oncogenesis.Viruses · 2026Review
- Expression of miR-92a and miR-125b and Their Association with Chemoradiotherapy Response in Locally Advanced Cervical Cancer.International journal of molecular sciences · 2026Article
- Cervical cancer immune microenvironment: Mechanisms of HPV-mediated immune evasion and advances in immunotherapy (Review).Oncology letters · 2026Review
- Unraveling the mechanisms of LncRNAs in cervical cancer: a comprehensive review.Cell death discovery · 2025Review
- Precision theranostics in cervical Cancer: Harnessing stimuli-responsive hydrogels for tumor microenvironment-targeted therapy and diagnosis.Materials today. Bio · 2025Review
- Elucidating Circular Ribonucleic Acid Mechanisms Associated with Splicing Factor 3 Inhibition in Cervical Cancer.International journal of molecular sciences · 2025Article
- Association between female HPV infection, inflammatory markers and depression: a cross-sectional and mediation analysis.BMC infectious diseases · 2025Article
- siRNA and mRNA-Based Preventive and Therapeutic Strategies for HPV-Induced Cervical Cancer.Advanced pharmaceutical bulletin · 2025Review
- Patient willingness to pay and preference for cervical cancer treatments among middle- and low-income populations in Xinjiang.Journal of patient-reported outcomes · 2025Article
- To explore the molecular mechanisms and shared genetic characteristics of rheumatoid arthritis and cervical cancer based on multiple omics and clinical samples.Discover oncology · 2025Article
- Leukocyte-specific protein 1 is associated with the stage and tumor immune infiltration of cervical cancer.Scientific reports · 2025Article
- HPV infection and the immune microenvironment in cervical cancer.Frontiers in immunology · 2025Review
- Profiling of immune cell subsets and functional characteristics of cervical cancer based on single cell RNA sequencing.Frontiers in immunology · 2025Article
- Conditioned media from human adipose tissue-derived mesenchymal stem cells: potential effect on peripheral blood mononuclear cells in co-culture with HeLa cell line.Cytotechnology · 2024Article
- Article
- Impact of baseline lymphopenia on outcomes of definitive treatment for locally advanced cervical cancer.Gynecologic oncology reports · 2024Article
- Circular RNAs and cervical cancer: friends or foes? A landscape on circRNA-mediated regulation of key signaling pathways involved in the onset and progression of HPV-related cervical neoplasms.Cell communication and signaling : CCS · 2024Review
- Immune Responses in Oral Papillomavirus Clearance in the MmuPV1 Mouse Model.Pathogens (Basel, Switzerland) · 2023Article
- TIME Is Ticking for Cervical Cancer.Biology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune cells are essential for defending the body's balance and have increasingly been implicated in controlling tumor growth. In cervical cancer (CC), the immune landscape is extensively connected with human papillomavirus (HPV) status. Recent insights from studies have revealed that as a result of infection with HPV, immune cell populations such as lymphocytes or monocytes change during carcinogenesis. Immune therapy, in particular checkpoint inhibitors, those targeting PD-1 or PD-L1, has shown promising efficacy. This article reviews the immune landscape and immunotherapy of CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.